Serelaxin + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Liver Cirrhosis
Conditions
Liver Cirrhosis, Hypertension, Portal
Trial Timeline
Oct 18, 2017 → Aug 31, 2018
NCT ID
NCT02669875About Serelaxin + Placebo
Serelaxin + Placebo is a phase 2 stage product being developed by Novartis for Liver Cirrhosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02669875. Target conditions include Liver Cirrhosis, Hypertension, Portal.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02669875 | Phase 2 | Completed |
| NCT02625922 | Phase 2 | Terminated |
| NCT02007720 | Phase 3 | Terminated |
| NCT02002702 | Phase 2 | Completed |
| NCT00259103 | Phase 2 | Completed |
Competing Products
20 competing products in Liver Cirrhosis